Evaluate the effects of a medication, tolcapone (TOLC), on non-treatment-seeking individuals with Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder (ADHD).
This study evaluates the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During the study period there will be two fMRI scans and two on-campus alcohol administration sessions. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD.
Age 21-65 and not currently seeking or engaged in treatment for Alcohol Use Disorder (AUD) or Attention-Deficit/Hyperactivity Disorder (ADHD). Please contact the Translational Addiction Imaging Laboratory (TrAIL Lab) at alcoholstudy@ucdenver.edu for more information about the study and additional eligibility criteria.
Principal Investigator